Biochemical

AOD 9604 221231-10-3 Anti-Obesity Drug


Product name AOD 9604
Synonyms AOD 9604; hGH Fragment 177-191
CAS NO 221231-10-3
Assay 95%
Certification ISO9001
Brand Name NJBNsteroid
Appearance White powder
Usage Anti-Obesity Drug

Product Description:

AOD9604 is a peptide fragment (H Fragment 177-191) of the C-terminus of Human G H to which a tyrosine is added at the N-terminal end. Studies have suggested that AOD9604 is more effective than its predecessor AOD9401 in its ability to stimulate lipolytic (fat burning) and anti-lipogenic activity. Like G H, AOD9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (prevents the transformation of fatty food materials into body fat) both in laboratory testing and in animals and humans. Recent clinical research studies have shown that AOD9604 did show a reduction of body fat in the mid abdominal area in both obese, over-weight, and average built people.

Investigators discovered that the fat-reducing effects of GH appear to be controlled by a small region near one end of the GH molecule. This region, which consists of amino acids 177-191, is less than 10% of the total size of the GH molecule and appears to have no effect on growth or insulin resistance. It works by mimicking the way natural G H regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified G H.


Product Applications:

AOD9604 is a peptide (a chain of amino acids) which was developed and patented by a company called Metabolic Pharmaceuticals in Australia in the late 1990s. AOD stands for & quot;Anti Obesity Drug& quot;. This peptide has an amino acid sequence